Cover Image

Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials

Background: Whereas the cardiovascular safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors has been well reported, there is limited data from controlled clinical trials regarding the non-cardiovascular safety. This was the focus of our study.Methods and Findings: We systematically searched...

Full description

Saved in:

Bibliographic Details
Main Authors:	Fang-Hong Shi (Author), Hao Li (Author), Long Shen (Author), Zhen Zhang (Author), Yi-Hong Jiang (Author), Yao-Min Hu (Author), Xiao-Yan Liu (Author), Zhi-Chun Gu (Author), Jing Ma (Author), Hou-Wen Lin (Author)
Format:	Book
Published:	Frontiers Media S.A., 2019-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sodium-Glucose Co-Transporter 2 Inhibitors Use Improves the Satisfaction With Anti-diabetic Agent Treatment: A Questionnaire-based Propensity Score-matched Study
by: Fang-Hong Shi, et al.
Published: (2022)

Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis
by: Fan Yang, et al.
Published: (2023)

Sodium-glucose co-transporter 2 inhibitors - a review article
by: Marcin Makuch, et al.
Published: (2019)

Sodium-glucose co-transporter 2 inhibitors - a review article
by: Marcin Makuch, et al.
Published: (2019)

Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
by: Yuling Jing, et al.
Published: (2022)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
by: Daniel H. Van Raalte, et al.
Published: (2022)

Sodium glucose co-transporter 2 inhibitors in heart failure therapy
by: Yüksel Çavuşoğlu, et al.
Published: (2020)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
by: Nunzia D'Onofrio, et al.
Published: (2021)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
by: Sarah L. Armour, et al.
Published: (2022)

A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitors
by: Xueting Yao, et al.
Published: (2023)

Glucose transporters and sodium glucose co-transporters cooperatively import glucose into energy-demanding organs in carcinogenic liver fluke Clonorchis sinensis.
by: Fuhong Dai, et al.
Published: (2024)

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
by: Yangli Ye, et al.
Published: (2019)

Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
by: Stephen Melnick, et al.
Published: (2018)

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
by: Lu Chen, et al.
Published: (2020)

Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
by: Anthony T. P. Chan, et al.
Published: (2022)

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials
by: Wei Qu, et al.
Published: (2021)

An appraisal of the current status of inhibition of glucose transporters as an emerging antineoplastic approach: Promising potential of new pan-GLUT inhibitors
by: Mithlesh Kumar Temre, et al.
Published: (2022)

Intervention by clinical pharmacists can improve blood glucose fluctuation in patients with diabetes and acute myocardial infarction: A propensity score‐matched analysis
by: Fang‐Hong Shi, et al.
Published: (2021)

Metabolic reprogramming as the basis for sodium-glucose co-transporter type 2 inhibitors cardio- and nephroprotective effect
by: O N. Kurochkina, et al.
Published: (2024)

Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews
by: Ryan Pelletier, et al.
Published: (2021)

The clinical cases of ketoacidosis in patients with 2 type diabetes treated with inhibitors of sodium-glucose co-transporter
by: Diana Sh. Avzaletdinova, et al.
Published: (2021)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
by: Sanon VP, et al.
Published: (2017)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
by: Chun Xing Li, et al.
Published: (2023)

Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis
by: Lei Tian, et al.
Published: (2022)

The analysis of a wide spectrum of activity of Sodium-Glucose co-transporter-2 inhibitors. A literature review
by: Magdalena Kozioł, et al.
Published: (2020)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents
by: Eva M Vivian
Published: (2014)

Polypharmacology of clinical sodium glucose co‐transport protein 2 inhibitors and relationship to suspected adverse drug reactions
by: Karan Matharu, et al.
Published: (2021)

Sodium-glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review
by: Magdalena Kłusek, et al.
Published: (2024)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022)

The effect of sodium glucose Co-transport 2 inhibitors on cognitive impairment and depression in type 2 diabetes mellitus patients
by: Ashurova Nodirahon, et al.
Published: (2024)

A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors
by: D. P. Golubovskaya, et al.
Published: (2022)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
by: Joshua J Neumiller
Published: (2014)

Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus
by: Mohammed Ali Gameil, et al.
Published: (2020)

Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans
by: Min-Soo Kim, et al.
Published: (2023)

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease
by: Gabriela Dumitrita Stanciu, et al.
Published: (2023)

The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes
by: Masahiko Iwamoto, et al.
Published: (2022)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018)

In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: Inhibition kinetics and binding studies
by: Saeko Uchida, et al.
Published: (2015)

Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease
by: Rabab Mahmoud Ahmed, et al.
Published: (2024)

Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice.
by: Beata Jacuś, et al.
Published: (2021)